| Maraviroc - Wikipedia, the free encyclopedia Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is an antiretroviral drug in the CCR5 receptor antagonist class used in the treatment of HIV infection. Read More |
| SELZENTRY® (maraviroc) | Official Website Learn more about SELZENTRY® (maraviroc). Find information on dosing, side effects, safety and savings programs. Read More |
| Maraviroc | HIV/AIDS Drug | Patient | AIDSinfo Maraviroc, also known as Selzentry, is a type of medicine called an entry inhibitor. Entry inhibitors work by blocking HIV from entering human cells. Read More |
| Maraviroc: MedlinePlus Drug Information - National Library of ... Maraviroc may cause damage to your liver. You may experience an allergic reaction to maraviroc before you develop liver damage. Tell your doctor if you ... Read More |
| Maraviroc (Selzentry, Celsentri) - HIV InSite Gateway to HIV and ... Approval: Maraviroc received accelerated approval from the U.S. Food and Drug Administration (FDA) in August 2007 for use in treating adults with CCR5-tropic HIV-1 ... Read More |
| Maraviroc Facts and Comparisons at Drugs.com All about Maraviroc. View complete and up to date Maraviroc information - part of the Drugs.com trusted medication database. Read More |
| maraviroc medical facts from Drugs.com Physician reviewed maraviroc patient information - includes maraviroc description, dosage and directions. Read More |
| Maraviroc - PubMed Health - National Center for Biotechnology ... Maraviroc is used with other medications to treat human immunodeficiency virus (HIV) in patients with or without acquired immunodeficiency syndrome (AIDS). Read More |
| File:Maraviroc.svg - Wikipedia, the free encyclopedia This is a file from the Wikimedia Commons. Information from its description page there is shown below. Commons is a freely licensed media file repository. You can help. Read More |
| Selzentry (Maraviroc) - HOME | hivandhepatitis.com CD4+ Cell Increases at 48 Weeks in the Maraviroc Treatment-naive MERIT Trial - 11/05/2008 Adverse Event Profile of Maraviroc in Treatment ... Read More |
